I-Rimegepant iyi-inhibitor encane ye-moleculei-calcitonini-peptide ehlobene nezakhi zofuzo (CGRP) receptor evimbela isenzo se-CGRP, i-vasodilator enamandla okukholelwa ukuthi idlala indima ekuphathweni kwekhanda elibuhlungu.I-Rimegepant igunyazwe ukwelapha ukuhlaselwa kwe-acute migraine.Ezivivinyweni zomtholampilo, i-rimegepant ngokuvamile yabekezelelwa kahle ngezimo ezingavamile kuphela zokuphakama kwe-serum aminotransferase yesikhashana phakathi nokwelashwa futhi ngaphandle kwezimo ezibikiwe zokulimala kwesibindi okubonakala ngokomtholampilo.

U-Rimegepant ungumphikisi womlomo we-CGRP receptor eyakhiwe yi-Biohaven Pharmaceuticals.Ithole imvume ye-FDA ngoFebhuwari 27, 2020 yokwelashwa okubuhlungu kwekhanda elibuhlungu lekhanda elibuhlungu.Nakuba abaphikisi abambalwa babazali be-CGRP kanye ne-receptor yayo bavunyelwe ukwelashwa kwe-migraine (isb. [erenumab], [fremanezumab], [galcanezumab]), i-rimegepant kanye [i-ubrogepant] ukuphela kwamalungu omndeni "we-gepants" wemithi esele isakhiwa, futhi okuwukuphela kwabaphikisi be-CGRP abanokutholakala kwe-oral bioavailability.Izinga lamanje lokwelashwa kwe-migraine lihilela ukwelashwa kokukhipha isisu ngama-"triptans", afana [i-sumatriptan], kodwa le mithi iphikisana neziguli ezine-cerebrovascular kanye nesifo senhliziyo esivele sikhona ngenxa yezakhiwo zabo ze-vasoconstrictive.Ukuphikiswa kwendlela ye-CGRP sekuphenduke into ekhangayo yokwelashwa kwe-migraine njengoba, ngokungafani nama-triptans, abaphikisi be-CGRP bomlomo abanazo izici ze-vasoconstrictive eziphawuliwe ngakho-ke ziphephile ukusetshenziswa ezigulini ezinokuphambana nokwelashwa okujwayelekile.

I-Rimegepant aI-CalcitoninI-Peptide Receptor Antagonist ehlobene neGene.Indlela yokusebenza ye-rimegepant ifana ne-aI-CalcitoninI-Peptide Receptor Antagonist ehlobene neGene.